Phase I-II trial of TLK286 (telcyta), carboplatin (C), and paclitaxel (P) as first-line treatment for advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Sequist, L
Fidias, P
Temel, J
Kennedy, E
Ostler, P
Rabin, M
Huberman, M
Keck, J
Brown, G
Lynch, T
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[4] Telik Inc, Palo Alto, CA USA
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S269 / S269
页数：1
相关论文
共 50 条
  • [31] Results of a randomized, phase III trial of nab-paclitaxel (nab-P) and carboplatin (C) compared with cremophor-based paclitaxel (P) and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC)
    Socinski, M. A.
    Bondarenko, I. N.
    Karaseva, N. A.
    Makhson, A.
    Vynnichenko, I.
    Okamoto, I.
    Hon, J. K.
    Hirsh, V.
    Bhar, P.
    Iglesias, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [32] Results of a phase I/II trial of carboplatin/gemcitabine plus celecoxib for first-line treatment of stage IIIB/IV non-small cell lung cancer (NSCLC).
    Burton, JD
    El-Sayah, D
    Cherry, M
    Bhargava, M
    Terjanian, T
    Odaimi, M
    Vesoniaraki, M
    Lowry, J
    Forte, F
    Friscia, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 682S - 682S
  • [33] Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer a multicenter, randomized, phase II trial
    Scagliotti, GV
    Kortsik, C
    Dark, GG
    Price, A
    Manegold, C
    Rosell, R
    O'Brien, M
    Peterson, PM
    Castellano, D
    Selvaggi, G
    Novello, S
    Blatter, J
    Kayitalire, L
    Crino, L
    Paz-Ares, L
    CLINICAL CANCER RESEARCH, 2005, 11 (02) : 690 - 696
  • [34] Paclitaxel and carboplatin in combination with gemcitabine: A phase I-II trial in patients with advanced non-small-cell lung cancer
    Favaretto, A
    Ceresoli, GL
    Paccagnella, A
    Barbieri, F
    Bearz, A
    Ghiotto, C
    Oniga, F
    Schiavon, S
    Frustaci, S
    Villa, E
    ANNALS OF ONCOLOGY, 2000, 11 (11) : 1421 - 1426
  • [35] A phase I-II study with carboplatin (C) and weekly paclitaxel (P) in advanced NSCLC
    Fabi, A
    Barduagni, M
    De Marco, S
    De Marinis, F
    Cortesi, E
    Foggi, CM
    Chiapparino, E
    Gareri, R
    Venturoli, AL
    Cognetti, F
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S263 - S264
  • [36] Combination of paclitaxel and etoposide in the treatment of advanced non-small cell lung cancer:: A phase I-II study
    Nanni, L
    Palomba, G
    Morelli, F
    Piano, A
    Simeone, A
    D'Alessandro, V
    Sirotovà, Z
    Capuano, G
    Rinaldi, B
    Lelli, G
    JOURNAL OF CHEMOTHERAPY, 2001, 13 (01) : 88 - 92
  • [37] Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell Lung Cancer
    Reynolds, Craig
    Barrera, David
    Jotte, Robert
    Spira, Alexander I.
    Weissman, Charles
    Boehm, Kristi A.
    Pritchard, Sharon
    Asmar, Lina
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (12) : 1537 - 1543
  • [38] Phase I/II study of atrasentan (A) in combination with carboplatin (C) and paclitaxel (P) in chemonaive patients (pts) with advanced non-small cell lung cancer (NSCLC).
    Chiappori, A
    Haura, E
    Williams, C
    Simon, G
    Antonia, S
    Cantor, A
    Burton, MK
    Lush, R
    Sullivan, DM
    Bepler, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 646S - 646S
  • [39] A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer
    Kelly, K
    Mikhaeel-Kamel, N
    Pan, ZX
    Murphy, J
    Prindiville, S
    Bunn, PA
    CLINICAL CANCER RESEARCH, 2000, 6 (09) : 3474 - 3479
  • [40] Phase I/II study of atrasentan, an endothelin a receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer
    Chiappori, Alberto A.
    Haura, Eric
    Rodriguez, FranciscoA.
    Boulware, David
    Kapoor, Rachna
    Neuger, Anthony M.
    Lush, Richard
    Padilla, Barbara
    Burton, Michelle
    Williams, Charles
    Simon, George
    Antonia, Scott
    Sullivan, Daniel M.
    Bepler, Gerold
    CLINICAL CANCER RESEARCH, 2008, 14 (05) : 1464 - 1469
12345